<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584519</url>
  </required_header>
  <id_info>
    <org_study_id>A1281162</org_study_id>
    <nct_id>NCT00584519</nct_id>
  </id_info>
  <brief_title>Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight</brief_title>
  <acronym>CRESSOB</acronym>
  <official_title>Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight (CRESSOB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette
      smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with
      overweight for 12 months.

      To analyse the perceived health status and the level of functioning and disability of
      patients with schizophrenia and overweight and their progress at 3, 6 and 12 months.

      To assess the progress of the symptoms of the disease at 6 and 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patient sampling. Any investigational site four consecutive patients with
      diagnosis of Schizophrenia (DSM-IV TR) and Overweight (BMI more or equal to 25 Kg/m2)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Risk</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the progress of the symptoms and clinical evolution of the disease</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Functional Impairment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current Pattern of Treatment in this Population</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">430</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>500 patients</arm_group_label>
    <description>Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional</intervention_name>
    <description>non-interventional</description>
    <arm_group_label>500 patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample. Patients &gt;17 years older with diagnosis of Schizophrenia (DSM-IV TR) and
        Overweight (BMI more or equal to 25 Kg/m2)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder
             (DSM-IV TR)

          -  Patients with BMI (body mass index) more or equal to 25 Kg/m2

          -  Patients or their legal representative have provided written informed consent

        Exclusion Criteria:

          -  Patients are unable to complete or to understand health questionnaires in Spanish
             language

          -  Patients are currently enrolled on clinical trials or other investigational studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281162&amp;StudyName=Control%20of%20Metabolic%20and%20Cardiovascular%20Risk%20in%20Patients%20with%20Schizophrenia%20and%20Overweight</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <keyword>Schizophrenia, Overweight, Cardiovascular Risk, Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

